AstraZeneca/$AZN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AstraZeneca
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
- Ticker
- $AZN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 96,100
- Headquarters
- Cambridge, United Kingdom
- Website
- www.astrazeneca.com
AstraZeneca Metrics
BasicAdvanced
$290B
26.44
$7.06
0.21
$3.23
1.14%
Price and volume
Market cap
$290B
Beta
0.21
52-week high
$212.71
52-week low
$153.41
Average daily volume
2.9M
Dividend rate
$3.23
Financial strength
Current ratio
1.006
Quick ratio
0.785
Long term debt to equity
0.558
Total debt to equity
0.662
Dividend payout ratio (TTM)
43.82%
Interest coverage (TTM)
11.05%
Profitability
EBITDA (TTM)
21,280
Gross margin (TTM)
81.78%
Net profit margin (TTM)
17.68%
Operating margin (TTM)
25.80%
Effective tax rate (TTM)
17.04%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
8.58%
Return on equity (TTM)
22.57%
Valuation
Price to earnings (TTM)
26.439
Price to revenue (TTM)
4.638
Price to book
4.19
Price to tangible book (TTM)
-28.58
Price to free cash flow (TTM)
45.798
Free cash flow yield (TTM)
2.18%
Free cash flow per share (TTM)
4.075
Dividend yield (TTM)
1.73%
Forward dividend yield
1.14%
Growth
Revenue change (TTM)
7.32%
Earnings per share change (TTM)
17.30%
3-year revenue growth (CAGR)
11.51%
10-year revenue growth (CAGR)
10.11%
3-year earnings per share growth (CAGR)
23.15%
10-year earnings per share growth (CAGR)
13.74%
3-year dividend per share growth (CAGR)
3.66%
10-year dividend per share growth (CAGR)
1.44%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Analyst projections of the future price of AstraZeneca stock.
Bulls say / Bears say
In the first nine months of 2026, revenue rose 7% and core EPS rose 14%; cancer medicines helped sustain momentum, with oncology sales up 17% in the third quarter. That growth shows the marketed portfolio is still expanding despite pressure on older drugs. (AstraZeneca, Euronews)
AstraZeneca’s experimental COPD drug tozorakimab cut moderate-to-severe flare-ups by about 29% to 34% in two late-stage trials. The positive results could give the company a new growth opportunity in a large disease market. (Reuters)
Tezspire met the main goals in a late-stage trial for eosinophilic oesophagitis, opening a potential use beyond its existing asthma market. A successful expansion would broaden the drug’s commercial reach. (Reuters)
US generic competition pushed Farxiga sales down 25% in the third quarter, while Brilinta is also losing patent protection. These older-drug declines may offset some of the growth from newer treatments. (Euronews, AstraZeneca)
China revenue fell 13% in the second quarter amid generic competition and policy changes, and AstraZeneca still cited Chinese volume-based procurement as a headwind in its nine-month update. Continued pressure there could weigh on growth in an important market. (Reuters, AstraZeneca)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
Upcoming events
No upcoming events
AstraZeneca News
AllArticlesVideos
Funds containing AstraZeneca
AllGBPEURUSD
Fund name | Fund size | $AZN weighting |
|---|---|---|
Vanguard FTSE 100£VUKE | £4.7B | 7.24% |
Vanguard FTSE 100£VUKG | £1.9B | 7.24% |
HSBC MSCI Europe Islamic Screened£HIPS | €144M | 4.19% |
HSBC MSCI Europe Islamic Screened$HIEU | €144M | 4.19% |
SPDR MSCI World Health Care$WHEA | $708M | 2.91% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.